Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0GUSX)

Drug Name
Ranitidine Drug Info
Synonyms
Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Therapeutic ClassAntiulcer Agents
Cross-matching ID
PubChem CID
3001055
ChEBI ID
CHEMBL8776
CAS Number
CAS 82530-72-1
TTD Drug ID
D0B8WN
VARIDT Drug ID
DR00163
INTEDE Drug ID
DR1393
ACDINA Drug ID
D00583

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Glycolysis / Gluconeogenesis 2.09 0.00e+0 56/67 (83.58%) PGAM1;DLD;ALDH3A2;...
Cell cycle 1.97 0.00e+0 110/124 (88.71%) PCNA;E2F2;CCNB1;...
Citrate cycle (TCA cycle) 1.94 0.00e+0 30/30 (100%) DLD;IDH2;CS;...
DNA replication 1.93 0.00e+0 34/36 (94.44%) PCNA;RFC3;MCM6;...
beta-Alanine metabolism 1.87 7.25e-3 25/30 (83.33%) ALDH6A1;ALDH3A2;ECHS1;...
Tyrosine metabolism 1.84 8.05e-3 30/36 (83.33%) MAOA;TYRP1;ADH1B;...
Pyruvate metabolism 1.83 8.63e-3 41/47 (87.23%) DLD;GLO1;ALDH3A2;...
Mismatch repair 1.80 1.06e-2 22/23 (95.65%) PCNA;RFC3;POLD2;...
Propanoate metabolism 1.78 1.34e-2 30/34 (88.24%) DLD;ALDH6A1;ECHS1;...
African trypanosomiasis 1.78 1.45e-2 32/37 (86.49%) PLCB1;LAMA4;IFNG;...
Lysine degradation 1.76 1.98e-2 51/63 (80.95%) DLD;ALDH3A2;PLOD2;...
T cell receptor signaling pathway 1.75 2.21e-2 93/104 (89.42%) NFATC3;RASGRP1;KRAS;...
Tryptophan metabolism 1.74 2.14e-2 35/42 (83.33%) AOC1;MAOA;DLD;...
Chemokine signaling pathway 1.71 2.93e-2 163/192 (84.9%) KRAS;CXCL3;CCL5;...
Retinol metabolism 1.69 3.38e-2 41/68 (60.29%) ALDH1A2;DHRS9;ADH1B;...
Viral protein interaction with cytokine and cytokine re... 1.69 3.17e-2 84/100 (84%) CXCL3;CCL5;CCL20;...
Metabolism of xenobiotics by cytochrome P450 1.69 2.98e-2 49/77 (63.64%) GSTA4;ADH1B;ADH5;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H